Acta cardiologica最新文献_第8页

The association between peak tricuspid regurgitation velocity and 1-year heart failure readmission in hospitalised patients with heart failure with preserved ejection fraction. 射血分数保留型心力衰竭住院患者的三尖瓣反流峰值速度与 1 年心力衰竭再入院之间的关系。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2024-11-19 DOI: 10.1080/00015385.2024.2421638

Tianbo Wang, Xiaohan Liu, Yue Zhang, Chenli Fang, Junbo Xu

{"title":"The association between peak tricuspid regurgitation velocity and 1-year heart failure readmission in hospitalised patients with heart failure with preserved ejection fraction.","authors":"Tianbo Wang, Xiaohan Liu, Yue Zhang, Chenli Fang, Junbo Xu","doi":"10.1080/00015385.2024.2421638","DOIUrl":"10.1080/00015385.2024.2421638","url":null,"abstract":"Background: This study aimed to evaluate the association between peak tricuspid regurgitation velocity (TRV) and 1-year heart failure (HF) readmission in hospitalised patients with HF with preserved ejection fraction (HFpEF) because the impact of peak TRV on the short-term prognosis of these patients has been unclear.Methods: From January 2020 to December 2021, 513 hospitalised HFpEF patients age ≥ 60 years with 1-year follow-up were included in this study. Peak TRV was classified as normal (≤ 2.8 m/s) and high (> 2.8 m/s) value according to pulmonary hypertension probability.Results: Approximately 68.23% of HFpEF patients had a high peak TRV value. In the final adjusted Cox regression model, peak TRV was still independently associated with HF readmission (HR: 1.74, 95% CI: 1.19-2.55, p = 0.004). Furthermore, patients with high peak TRV were also associated with an increased risk of HF readmission (HR: 2.30, 95% CI: 1.31-4.04, p = 0.004), compared to those with normal peak TRV. After inverse probability of weighting, the risk of HF readmission in patients with high peak TRV was 2.53 (95% CI: 1.35-4.75, p = 0.004) compared to those with normal peak TRV. Additionally, Subgroup analysis revealed very elderly patients, male, and patients with hypertension had a significantly worse prognosis.Conclusion: Peak TRV is independently associated with HF readmission in hospitalised HFpEF patients. High peak TRV has a higher risk of HF readmission in patients age ≥ 80 years, male and patients with hypertension, indicating that special attention should be paid to these patients.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"217-224"},"PeriodicalIF":2.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-in-man concomitant mitral transcatheter edge-to-edge repair and atrial fibrillation ablation. 二尖瓣经导管边缘对边缘修复和房颤消融的首次合并。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2025-02-26 DOI: 10.1080/00015385.2025.2471651

Kyriakos Dimitriadis, Stergios Soulaidopoulos, Nikolaos Pyrpyris, Eirini Beneki, Dimitrios Tsiachris, Konstantinos Aznaouridis, Konstantina Aggeli, Konstantinos Tsioufis

引用次数: 0

Severe tricuspid regurgitation and right heart failure secondary to carcinoid heart disease. 继发于类癌心脏病的严重三尖瓣反流和右心衰竭。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2024-08-29 DOI: 10.1080/00015385.2024.2396757

Cian Murray, James Mannion, Mark Wilkinson

引用次数: 0

Staging cardiac damage in aortic stenosis: stratifying prognosis to individualise the treatment. 主动脉瓣狭窄的心脏损害分期：分层预后以个体化治疗。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2025-01-25 DOI: 10.1080/00015385.2025.2457178

Tommaso Viva, Simona Sperlongano, Mai-Linh Nguyen Trung, Hélène Petitjean, Patrizio Lancellotti

引用次数: 0

Coexisting bicuspid pulmonary and aortic valves. 肺动脉瓣和主动脉瓣双瓣并存。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2024-10-25 DOI: 10.1080/00015385.2024.2414132

Simon Deffet, Raluca Dulgheru, Patrizio Lancellotti

引用次数: 0

Complete heart block after occlusion and repair for perimembranous ventricular septal defect. 膜周围室间隔缺损的完全性心脏传导阻滞和修复。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/00015385.2025.2480961

Li Lin, Wanhua Chen, Hang Chen, Jianwen Liu, Kanghui Chen, Lianglong Chen, Liangwan Chen, Zhaoyang Chen

{"title":"Complete heart block after occlusion and repair for perimembranous ventricular septal defect.","authors":"Li Lin, Wanhua Chen, Hang Chen, Jianwen Liu, Kanghui Chen, Lianglong Chen, Liangwan Chen, Zhaoyang Chen","doi":"10.1080/00015385.2025.2480961","DOIUrl":"10.1080/00015385.2025.2480961","url":null,"abstract":"Background: Complete atrioventricular conduction block (CAVB) is a major complication of the repair and occlusion of perimembranous ventricular septal defects (pmVSDs).Objective: This study aimed to analyse the incidence and risk factors of CAVB after occlusion and repair of pmVSD.Methods: We reviewed patients with pmVSDs who underwent occlusion and repair between January 2010 and January 2022. Permanent CAVB was defined as a CAVB requiring permanent pacemaker implantation or occluder extraction.Results: Of 2436 patients who underwent pmVSD repair, 7 (0.3%) developed permanent CAVB. In all, 16 (0.7%) of the 2200 patients in the device group developed permanent CAVBs. All permanent CAVBs in the repair group occurred during hospital stay. In contrast, eight (50%) permanent CAVBs in the device group occurred over 1 month. A large pmVSD size (odds ratio [OR], 1.575; 95% confidence interval [CI], 1.260-1.970, p < 0.001) and device/defect ratio (OR, 2.608; 95% CI, 1.587-4.287, p < 0.001) were independent risk factors for permanent CAVB after surgical repair and device occlusion, respectively. Multivariate regression showed that device occlusion versus surgical repair was associated with a significantly higher risk of permanent CAVBs (OR, 4.675; 95% CI, 1.586-13.780, p = 0.005).Conclusion: The incidence rates of permanent CAVB after device occlusion and surgical repair were 0.7% and 0.3%, respectively. Large VSD size and device/defect ratio were independently associated with permanent CAVB after surgical repair and device occlusion, respectively. Compared with surgical repair, device occlusion was associated with a significantly higher risk of permanent CAVB after pmVSD closure.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"266-273"},"PeriodicalIF":2.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left atrial strain as a surrogate parameter for successful percutaneous ballon mitral valvotomy? 左心房应变作为经皮球囊二尖瓣切开术成功的替代参数？

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2025-04-02 DOI: 10.1080/00015385.2025.2484506

Bhagwati Prasad Pant, Rohit Walse, Harikrishnan Sivadasapillai, Sanjay Ganapathi, Ajitkumar Valaparambil

{"title":"Left atrial strain as a surrogate parameter for successful percutaneous ballon mitral valvotomy?","authors":"Bhagwati Prasad Pant, Rohit Walse, Harikrishnan Sivadasapillai, Sanjay Ganapathi, Ajitkumar Valaparambil","doi":"10.1080/00015385.2025.2484506","DOIUrl":"10.1080/00015385.2025.2484506","url":null,"abstract":"Background: Severe mitral stenosis (MS) leads to morphological and functional changes in the left atrium (LA) causing dysfunction. Relieving mitral obstruction improves the LA mechanics and structural remodelling. However, this is not taken as a measure of successful Ballon Mitral Valvotomy (BMV) in clinical practice.Methods: We studied the relationship between LA strain and severe MS and the short-term effect of BMV on LA mechanics in a prospective observational single-centre study.Results: Peak atrial longitudinal strain (PALS) was impaired in patients (n = 40) with severe MS and improved 24 h following BMV (11.93 ± 3.29% vs 14.96 ± 3.59%, p < 0.001). There was a significant decrease in transmitral gradient (12.0 ± 4 mmHg vs 3.2 ± 1.6 mmHg, p < 0.001) and systolic pulmonary artery pressure (sPAP) (42.0 ± 8 mmHg vs 40.0 ± 4.8 mmHg, p < 0.001) after the procedure. Mitral valve area (1.03 ± 0.27 cm2 vs 1.81 ± 0.31 cm2, p < 0.001) significantly increased after the procedure. Peak atrial longitudinal strain failed to predict the success of the procedure as (AUC: 0.53; 95% CI, 0.32-0.75, p = 0.791). A cut-off value of 11.42% demonstrated a sensitivity of 64.7% and specificity of 66.7%. (R = 0.33; 95% CI 0.09, 0.6, p = 0.038).Conclusion: Peak atrial longitudinal strain shows a significant improvement following a successful BMV. This increase in values reflects an improvement in clinical status and function class in follow-up. While PALS offers promise, it has limitations. Therefore, it seems reasonable to consider PALS as a supportive indicator alongside established markers like MV area and pressure gradient for assessing procedural success.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"274-282"},"PeriodicalIF":2.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Three-dimensional transesophageal echocardiographic guided transcatheter puncture of the interatrial septum for mitral valve-in-valve replacement for mitral bioprosthetic valve failure. 三维经食管超声心动图引导下经导管穿刺房间隔进行二尖瓣内置换术治疗二尖瓣生物人工瓣膜衰竭。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2024-12-16 DOI: 10.1080/00015385.2024.2436722

Junyi Gao, Xiaojing Ma, Yafeng He, Juan Xia, Qian Song, Chen Chen

引用次数: 0

Five-leaflet tricuspid valve regurgitation. Transcatheter repair at once? 三尖瓣五叶反流。立即进行经导管修复？

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2024-08-29 DOI: 10.1080/00015385.2024.2396751

Kyriakos Dimitriadis, Eirini Beneki, Konstantinos Aznaouridis, Constantina Aggeli, Konstantinos Tsioufis

引用次数: 0

Vericiguat versus sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction in China: a cost-utility analysis. Vericiguat与sacubitril/缬沙坦在中国治疗心力衰竭并降低射血分数：成本效用分析

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/00015385.2025.2484848

Xingyuan Zhao, Nan Hu, Liying Wang, Zongling Xia

{"title":"Vericiguat versus sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction in China: a cost-utility analysis.","authors":"Xingyuan Zhao, Nan Hu, Liying Wang, Zongling Xia","doi":"10.1080/00015385.2025.2484848","DOIUrl":"10.1080/00015385.2025.2484848","url":null,"abstract":"Background: PARADIGM-HF and VICTORIA studies have shown that treatment with sacubitril/valsartan or vericiguat could reduce cardiovascular mortality and hospitalisation in the patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, the cost-utility analysis of adding sacubitril/valsartan or vericiguat to the standard treatment of heart failure in Chinese patients with HFrEF was still unclear.Methods: Based on the Chinese healthcare system, a multi-state Markov model has been established for the cost-utility analysis and compared with the results of VICTORIA study subgroups and relevant local data in China. This model simulated the direct medical costs and quality-adjusted life years (QALYs) of HFrEF patients over a period of 20 years, in which these patients were treated with the standard treatment of heart failure and either adding sacubitril/valsartan or vericiguat. Moreover, incremental cost-utility ratio (ICUR) and incremental net monetary benefit (INMB) were also analysed and the robustness of the results was verified by using sensitivity analysis.Results: In the base case study, according to the Chinese HFrEF patients, the total costs for the sacubitril/valsartan group and the vericiguat group were 4,237.42 USD and 4,618.59 USD, respectively, and the total utility was 3.62 and 3.48 QALYs, respectively. The ICUR was -2,611.68 USD/QALY, and the INMB was -5,772.32 USD. The sensitivity analysis indicated that the results were robust. The results of scenario analysis and base-case analysis were basically consistent.Conclusions: On the standard treatment of heart failure, adding sacubitril/valsartan alone was more cost-effective than adding vericiguat alone for the treatment of HFrEF.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"283-291"},"PeriodicalIF":2.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0